Creative Planning
PTCT icon

Creative Planning’s PTC Therapeutics PTCT Stock Holding History

Creative Planning’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-500
Closed -$2K – 4858
2016
Q4 		$2K Buy
+500
New +$5.25K ﹤0.01% 4293

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Creative Planning's PTCT Position: Q2 2026 in Review

Creative Planning increased its PTC Therapeutics (PTCT) stake by 32% in Q2 2026, buying an estimated $976K and bringing the position to 55,712 shares worth $4.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1485.

Creative Planning first reported a position in PTCT in Q1 2015 and has held it in 29 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Creative Planning held 55,712 shares of PTC Therapeutics worth $4.54M as of Q2 2026.
  • Creative Planning bought 13,516 PTC Therapeutics shares in Q2 2026, an estimated $976K.
  • PTC Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1485 holding.
  • Creative Planning first reported a position in PTC Therapeutics in Q1 2015 and has held it in 29 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.